Verrica Pharmaceuticals (VRCA) to Release Earnings on Monday

Verrica Pharmaceuticals (NASDAQ:VRCA) is expected to be announcing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect Verrica Pharmaceuticals to post earnings of ($1.14) per share and revenue of $8.3420 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Monday, November 3, 2025 at 9:30 AM ET.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its earnings results on Tuesday, August 12th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.72. The company had revenue of $12.70 million for the quarter, compared to analysts’ expectations of $4.37 million. On average, analysts expect Verrica Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verrica Pharmaceuticals Stock Up 2.3%

Shares of NASDAQ:VRCA opened at $3.61 on Friday. The business’s 50 day moving average is $4.54 and its 200 day moving average is $5.51. The stock has a market cap of $34.11 million, a P/E ratio of -0.44 and a beta of 1.71. Verrica Pharmaceuticals has a 52-week low of $3.43 and a 52-week high of $16.19.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $20.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC lifted its holdings in shares of Verrica Pharmaceuticals by 306.7% during the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock worth $26,000 after purchasing an additional 44,275 shares during the period. Qube Research & Technologies Ltd purchased a new position in Verrica Pharmaceuticals during the 2nd quarter worth approximately $28,000. Invesco Ltd. raised its position in Verrica Pharmaceuticals by 64.8% during the 1st quarter. Invesco Ltd. now owns 74,388 shares of the company’s stock worth $33,000 after buying an additional 29,256 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Verrica Pharmaceuticals by 23.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company’s stock valued at $61,000 after acquiring an additional 26,308 shares during the period. Finally, Marshall Wace LLP purchased a new stake in shares of Verrica Pharmaceuticals in the 2nd quarter valued at $66,000. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.